<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Normal Tension Glaucoma - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjXP8I3Gx5@JGrMzJzYQAAABQ","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Normal_Tension_Glaucoma","wgTitle":"Normal Tension Glaucoma","wgCurRevisionId":79297,"wgRevisionId":79297,"wgArticleId":965,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Normal_Tension_Glaucoma","wgRelevantArticleId":965,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],"wgRestrictionMove":[],"sdgDownArrowImage":
"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"srfFilteredConfig":null,
"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Normal tension glaucoma (NTG) is a common form of primary open angle glaucoma (POAG) in which there is no measured elevation of the intraocular pressure (IOP). The clinical characteristics of NTG have many similarities to those in POAG, with a few notable distinctions. Like POAG, NTG is a chronic, progressive optic neuropathy that results in a characteristic optic nerve head cupping, retinal nerve fiber layer thinning and functional visual field loss. Careful and complete review of history, physical exam findings, and diagnostic testing are key to distinguishing NTG from other common forms of glaucomatous and non-glaucomatous optic neuropathy. The role of IOP in the pathogenesis of NTG is an area of controversy prompting research into a variety of IOP independent factors such as vascular dysregulation, hypotension, and lamina cribrosa abnormalities that may have some role to play in the development of this disease. Therefore, other proposed interventions in NTG have aimed at modification of blood pressure and optic nerve perfusion in addition to neuroprotection as a means of slowing disease progression independent of an IOP lowering mechanism. Despite the lack of an observed IOP elevation, the current medical and surgical treatment of NTG continues to be aimed at lowering IOP as in other forms of POAG."/>
<meta name="date" content="2022-03-31"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Normal Tension Glaucoma" href="/w/index.php?title=Special:ExportRDF/Normal_Tension_Glaucoma&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Normal_Tension_Glaucoma rootpage-Normal_Tension_Glaucoma layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Normal+Tension+Glaucoma" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Normal+Tension+Glaucoma" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyxfad5"></button>
					<div class="collapse navbar-collapse hbpzyxfad5" id="hbpzyxfad5">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Normal_Tension_Glaucoma" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Normal_Tension_Glaucoma&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Normal_Tension_Glaucoma&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Normal_Tension_Glaucoma&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Normal_Tension_Glaucoma&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Normal_Tension_Glaucoma#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Normal Tension Glaucoma</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Leonard.K.Seibold" title="User:Leonard.K.Seibold">Leonard K. Seibold, MD</a>,&#8201;<a href="/User:Robert.U.Glazier" title="User:Robert.U.Glazier">Robert Udell Glazier Jr., MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Samuel.P.Solish.CMT" title="User:Samuel.P.Solish.CMT">Samuel P. Solish,MD</a>,&#160;<a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:John.Davis.Akkara" title="User:John.Davis.Akkara">Dr John Davis Akkara (MBBS, MS, FAEH, FMRF)</a>,&#160;<a href="/User:Leonard.K.Seibold" title="User:Leonard.K.Seibold">Leonard K. Seibold, MD</a>,&#160;<a href="/User:Shane.Nau" title="User:Shane.Nau">Shane Nau</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Leonard.K.Seibold" title="User:Leonard.K.Seibold">Leonard K. Seibold, MD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Update Pending</b>
</div>
</div>&#160;by <a href="/User:Leonard.K.Seibold" title="User:Leonard.K.Seibold">Leonard K. Seibold, MD</a> on April 1, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Normal_Tension_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Normal_Tension_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table> </div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Summary"><span class="tocnumber">1</span> <span class="toctext">Summary</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Disease_Entity"><span class="tocnumber">2</span> <span class="toctext">Disease Entity</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Intraocular_Pressure_in_the_Population"><span class="tocnumber">2.1</span> <span class="toctext">Intraocular Pressure in the Population</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Etiology"><span class="tocnumber">2.2</span> <span class="toctext">Etiology</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Risk_Factors"><span class="tocnumber">2.3</span> <span class="toctext">Risk Factors</span></a>
<ul>
<li class="toclevel-3 tocsection-6"><a href="#Optic_nerve_and_anatomical_features"><span class="tocnumber">2.3.1</span> <span class="toctext">Optic nerve and anatomical features</span></a></li>
<li class="toclevel-3 tocsection-7"><a href="#Intraocular_Pressure"><span class="tocnumber">2.3.2</span> <span class="toctext">Intraocular Pressure</span></a></li>
<li class="toclevel-3 tocsection-8"><a href="#Systemic_vascular_disease"><span class="tocnumber">2.3.3</span> <span class="toctext">Systemic vascular disease</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-9"><a href="#General_Pathology"><span class="tocnumber">2.4</span> <span class="toctext">General Pathology</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Pathophysiology"><span class="tocnumber">2.5</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Primary_prevention"><span class="tocnumber">2.6</span> <span class="toctext">Primary prevention</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-12"><a href="#Diagnosis"><span class="tocnumber">3</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2 tocsection-13"><a href="#History"><span class="tocnumber">3.1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Physical_examination"><span class="tocnumber">3.2</span> <span class="toctext">Physical examination</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Signs"><span class="tocnumber">3.3</span> <span class="toctext">Signs</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Symptoms"><span class="tocnumber">3.4</span> <span class="toctext">Symptoms</span></a></li>
<li class="toclevel-2 tocsection-17"><a href="#Clinical_diagnosis"><span class="tocnumber">3.5</span> <span class="toctext">Clinical diagnosis</span></a></li>
<li class="toclevel-2 tocsection-18"><a href="#Diagnostic_procedures"><span class="tocnumber">3.6</span> <span class="toctext">Diagnostic procedures</span></a>
<ul>
<li class="toclevel-3 tocsection-19"><a href="#Visual_field_testing"><span class="tocnumber">3.6.1</span> <span class="toctext">Visual field testing</span></a></li>
<li class="toclevel-3 tocsection-20"><a href="#Optic_disc_imaging"><span class="tocnumber">3.6.2</span> <span class="toctext">Optic disc imaging</span></a></li>
<li class="toclevel-3 tocsection-21"><a href="#Pachymetry"><span class="tocnumber">3.6.3</span> <span class="toctext">Pachymetry</span></a></li>
<li class="toclevel-3 tocsection-22"><a href="#Neurological_Evaluation.2FWork-Up"><span class="tocnumber">3.6.4</span> <span class="toctext">Neurological Evaluation/Work-Up</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-23"><a href="#Differential_diagnosis"><span class="tocnumber">3.7</span> <span class="toctext">Differential diagnosis</span></a>
<ul>
<li class="toclevel-3 tocsection-24"><a href="#Glaucomatous_etiology"><span class="tocnumber">3.7.1</span> <span class="toctext">Glaucomatous etiology</span></a></li>
<li class="toclevel-3 tocsection-25"><a href="#Compressive.2C_metabolic.2C_toxic.2C_inflammatory_or_infectious_optic_neuropathy"><span class="tocnumber">3.7.2</span> <span class="toctext">Compressive, metabolic, toxic, inflammatory or infectious optic neuropathy</span></a></li>
<li class="toclevel-3 tocsection-26"><a href="#Vascular_injuries"><span class="tocnumber">3.7.3</span> <span class="toctext">Vascular injuries</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-27"><a href="#Management"><span class="tocnumber">4</span> <span class="toctext">Management</span></a>
<ul>
<li class="toclevel-2 tocsection-28"><a href="#General_treatment"><span class="tocnumber">4.1</span> <span class="toctext">General treatment</span></a></li>
<li class="toclevel-2 tocsection-29"><a href="#Medical_therapy"><span class="tocnumber">4.2</span> <span class="toctext">Medical therapy</span></a></li>
<li class="toclevel-2 tocsection-30"><a href="#Medical_follow_up"><span class="tocnumber">4.3</span> <span class="toctext">Medical follow up</span></a></li>
<li class="toclevel-2 tocsection-31"><a href="#Surgery"><span class="tocnumber">4.4</span> <span class="toctext">Surgery</span></a></li>
<li class="toclevel-2 tocsection-32"><a href="#Prognosis"><span class="tocnumber">4.5</span> <span class="toctext">Prognosis</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-33"><a href="#References"><span class="tocnumber">5</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Summary">Summary</span></h1>
<p>Normal tension glaucoma (NTG) is a common form of primary open angle glaucoma (POAG) in which there is no measured elevation of the intraocular pressure (IOP). The clinical characteristics of NTG have many similarities to those in POAG, with a few notable distinctions. Like POAG, NTG is a chronic, progressive optic neuropathy that results in a characteristic optic nerve head cupping, retinal nerve fiber layer thinning and functional visual field loss. Careful and complete review of history, physical exam findings, and diagnostic testing are key to distinguishing NTG from other common forms of glaucomatous and non-glaucomatous optic neuropathy. The role of IOP in the pathogenesis of NTG is an area of controversy prompting research into a variety of IOP independent factors such as vascular dysregulation, hypotension, and lamina cribrosa abnormalities that may have some role to play in the development of this disease. Therefore, other proposed interventions in NTG have aimed at modification of blood pressure and optic nerve perfusion in addition to neuroprotection as a means of slowing disease progression independent of an IOP lowering mechanism. Despite the lack of an observed IOP elevation, the current medical and surgical treatment of NTG continues to be aimed at lowering IOP as in other forms of POAG. 
</p>
<h1><span class="mw-headline" id="Disease_Entity">Disease Entity</span></h1>
<p>Normal pressure glaucoma, an open angle glaucoma. 
</p>
<h2><span class="mw-headline" id="Intraocular_Pressure_in_the_Population">Intraocular Pressure in the Population</span></h2>
<p>Glaucomatous optic neuropathy is a clinical phenomenon without a single clear pathophysiologic mechanism. The term glaucoma is defined clinically as visual function loss in the setting of the characteristic ‘cupping’ of glaucomatous optic neuropathy. In the setting of an open anterior chamber angle (open angle glaucoma), these pathologic changes are observed over a range of normal, supernormal, and subnormal intraocular pressures. 
</p><p>Early recognition of glaucomatous optic neuropathy in the setting of physiologic intraocular pressure was described by Von Graefe in the mid 19th century<sup id="cite_ref-:1_1-0" class="reference"><a href="#cite_note-:1-1">&#91;1&#93;</a></sup>. Given the unclear etiology of the condition, many clinical definitions have been put forth guided by proposed mechanisms and efforts to describe the disease<sup id="cite_ref-:2_2-0" class="reference"><a href="#cite_note-:2-2">&#91;2&#93;</a></sup>. In 1980, Levene published an exhaustive critical review of the literature and personal cases leading to the widely used descriptive definition of normal tension glaucoma used today<sup id="cite_ref-:3_3-0" class="reference"><a href="#cite_note-:3-3">&#91;3&#93;</a></sup><sup id="cite_ref-:4_4-0" class="reference"><a href="#cite_note-:4-4">&#91;4&#93;</a></sup>. <br />Within the spectrum of primary open angle glaucoma, patients with physiologic intraocular pressures have been classified as having normal tension glaucoma (NTG) or, less accurately, low tension glaucoma (LTG). 
</p><p>As reliable tonometric means became available in the mid 20th century, large population based studies of intraocular pressure were performed<sup id="cite_ref-:5_5-0" class="reference"><a href="#cite_note-:5-5">&#91;5&#93;</a></sup><sup id="cite_ref-:6_6-0" class="reference"><a href="#cite_note-:6-6">&#91;6&#93;</a></sup><sup id="cite_ref-:7_7-0" class="reference"><a href="#cite_note-:7-7">&#91;7&#93;</a></sup><sup id="cite_ref-:8_8-0" class="reference"><a href="#cite_note-:8-8">&#91;8&#93;</a></sup><sup id="cite_ref-:9_9-0" class="reference"><a href="#cite_note-:9-9">&#91;9&#93;</a></sup><sup id="cite_ref-:10_10-0" class="reference"><a href="#cite_note-:10-10">&#91;10&#93;</a></sup><sup id="cite_ref-:11_11-0" class="reference"><a href="#cite_note-:11-11">&#91;11&#93;</a></sup><sup id="cite_ref-:12_12-0" class="reference"><a href="#cite_note-:12-12">&#91;12&#93;</a></sup><sup id="cite_ref-:13_13-0" class="reference"><a href="#cite_note-:13-13">&#91;13&#93;</a></sup><sup id="cite_ref-:14_14-0" class="reference"><a href="#cite_note-:14-14">&#91;14&#93;</a></sup><sup id="cite_ref-leydhecker15_15-0" class="reference"><a href="#cite_note-leydhecker15-15">&#91;15&#93;</a></sup>. Although the general distribution is skewed towards higher IOPs<sup id="cite_ref-leydhecker15_15-1" class="reference"><a href="#cite_note-leydhecker15-15">&#91;15&#93;</a></sup>, these studies have established the means to calculate the estimated range of physiologic IOP. Assuming a normal “Gaussian” distribution of intraocular pressure, a consensus has emerged defining the upper limit of normal IOP to be ~21 mmHg (2 standard deviations above the mean). Establishment of these norms has revealed that a significant portion of POAG patients have normal pressures as demonstrated in the Baltimore eye survey where 50% of patients identified with POAG had untreated IOP of &lt;22 mmHg.<sup id="cite_ref-:16_16-0" class="reference"><a href="#cite_note-:16-16">&#91;16&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Etiology">Etiology</span></h2>
<p>The development of glaucomatous optic neuropathy in general likely results from several factors that are mechanical, vascular or neurodegenerative in origin. Despite the lack of a single identifiable causal process, increased intraocular pressure has been identified as the most important modifiable risk factor in open angle glaucoma. The pathologic changes that occur in normal tension glaucoma are even less understood, but likely share contributing factors with all POAG. A host of causative factors independent to IOP have been suggested including systemic and local vascular dysregulation, hematologic abnormalities, impaired CSF circulation resulting in stagnation and decreased optic nerve protection, and structural anomalies including structural weakness of the lamina cribrosa. Drance and colleagues described two forms of NTG: 1) a non-progressive form typically associated with a transient episode of vascular compromise, and 2) a progressive form thought to result from a chronic vascular insufficiency at the optic nerve<sup id="cite_ref-drance17_17-0" class="reference"><a href="#cite_note-drance17-17">&#91;17&#93;</a></sup>. 
</p><p>It has been theorized that the disease process in NTG results from an enhanced sensitivity to what would otherwise be physiologic IOP, resulting in glaucomatous damage of the optic nerve. This enhanced sensitivity may be due to impaired optic nerve blood flow, a higher translaminar pressure gradient (IOP-ICP) due to lower ICP, or a structurally abnormal lamina cribrosa, which cannot withstand a normal range of IOP. This theory of enhanced sensitivity is useful, at least conceptually, to rationalize the impact of IOP in a disease process that may indeed have an IOP independent underlying etiology. The evidence for a role of IOP contributing to the disease comes from the Collaborative Normal Tension Glaucoma Study<sup id="cite_ref-ntgsg18_18-0" class="reference"><a href="#cite_note-ntgsg18-18">&#91;18&#93;</a></sup><sup id="cite_ref-ntgsg19_19-0" class="reference"><a href="#cite_note-ntgsg19-19">&#91;19&#93;</a></sup>, which showed a slowing of disease progression in patients achieving a 30% or more reduction of already normal IOP. While some try to delineate NTG and POAG as two completely unique disease processes, it has also been suggested that the diseases exist on a continuum with IOP playing a larger role in POAG, and vascular or mechanical factors at the etiologic root in NTG.
</p>
<h2><span class="mw-headline" id="Risk_Factors">Risk Factors</span></h2>
<h3><span class="mw-headline" id="Optic_nerve_and_anatomical_features">Optic nerve and anatomical features</span></h3>
<p>Though the quantity of axons that compose optic nerves in humans remains a predictable constant between individuals, variability in surface area of optic discs is observed. It is unclear if certain optic nerve head parameters place an eye at increased risk of NTG. Optic nerves with a larger surface area and with thinner inferior/inferotemporal rims have been reported to be at an increased risk for developing NTG.<sup id="cite_ref-:20_20-0" class="reference"><a href="#cite_note-:20-20">&#91;20&#93;</a></sup><sup id="cite_ref-:21_21-0" class="reference"><a href="#cite_note-:21-21">&#91;21&#93;</a></sup> Other studies evaluating the optic nerve head by scanning laser ophthalmoscopy found no morphologic differences between high-tension and normal tension glaucoma patients<sup id="cite_ref-:22_22-0" class="reference"><a href="#cite_note-:22-22">&#91;22&#93;</a></sup>. 
</p><p>Frequently an area of peripapillary atrophy in a crescent or halo configuration is observed in patients with NTG. While this pattern of atrophy can be a finding in eyes without NTG, in glaucomatous eyes, peripapillary atrophy often occurs adjacent to areas of greatest disc thinning and corresponding visual field loss<sup id="cite_ref-:23_23-0" class="reference"><a href="#cite_note-:23-23">&#91;23&#93;</a></sup>. While thinning of the optic nerve rim is observed in all POAG, focal thinning or ‘notching’ is more commonly observed in NTG.<sup id="cite_ref-:24_24-0" class="reference"><a href="#cite_note-:24-24">&#91;24&#93;</a></sup>
</p><p>Classically, the presence of small flame shaped optic disc hemorrhages, also known as Drance hemorrhages, has been associated with NTG though this finding can be observed in any form of POAG. Anderson et al reported the presence of optic disc hemorrhages at the time of diagnosis of NTG as an unfavorable prognostic marker for likely visual field progression.<sup id="cite_ref-:25_25-0" class="reference"><a href="#cite_note-:25-25">&#91;25&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Intraocular_Pressure">Intraocular Pressure</span></h3>
<p>Although always residing within the normal range for IOP, patients with NTG have been suggested to have higher-normal IOP levels<sup id="cite_ref-gramer26_26-0" class="reference"><a href="#cite_note-gramer26-26">&#91;26&#93;</a></sup>. By contrast, prospective evaluation of patients in the Low-Pressure Glaucoma Treatment Study found no relation between IOP asymmetry and visual field asymmetry<sup id="cite_ref-krupin27_27-0" class="reference"><a href="#cite_note-krupin27-27">&#91;27&#93;</a></sup>. Wide diurnal fluctuations in IOP and nocturnal IOP spikes have also been correlated with NTG<sup id="cite_ref-gramer26_26-1" class="reference"><a href="#cite_note-gramer26-26">&#91;26&#93;</a></sup>.
</p>
<h3><span class="mw-headline" id="Systemic_vascular_disease">Systemic vascular disease</span></h3>
<p>Patients with systemic conditions that result in ischemic vascular disease such as diabetes and patients with a history of stroke have been shown to be at increased risk for bilateral NTG compared to unilateral NTG . Patients with NTG may have increased diastolic blood pressure and display larger dips in blood pressure overnight compared to normal . Similarly, it has been suggested that Obstructive Sleep Apnea (OSA) may lead to transient episodes of nocturnal hypoxemia and compromised optic nerve head perfusion. In fact, a higher prevalence of OSA among NTG patients has been noted in several studies <sup>[58] [59] [60]</sup>. Moreover, one study demonstrated a correlation between moderate/severe OSA and higher progression of RNFL loss <sup>[61]</sup>. 
</p><p>Certain vasospastic conditions such as Raynaud phenomenon are thought to be associated with NTG, with the most reported associated condition being migraine.<sup id="cite_ref-:31_28-0" class="reference"><a href="#cite_note-:31-28">&#91;28&#93;</a></sup> Recently, a disease entity termed primary vascular dysregulation (PVD) has been described pointing to retinal and optic nerve vasculature dysregulation as a potential risk factor for NTG<sup id="cite_ref-:32_29-0" class="reference"><a href="#cite_note-:32-29">&#91;29&#93;</a></sup>
.
</p>
<h2><span class="mw-headline" id="General_Pathology">General Pathology</span></h2>
<p>Specific histological studies of eyes with NTG are sparse but in general mimic those changes seen in POAG. Histopathologic changes of the optic nerve head include disarrangement and posterior bowing of the lamina cribrosa along with loss of nerve fibers<sup id="cite_ref-:33_30-0" class="reference"><a href="#cite_note-:33-30">&#91;30&#93;</a></sup>. Non-invasive imaging by OCT and scanning laser modalities have characterized thinning of the peripapillary choroid<sup id="cite_ref-:34_31-0" class="reference"><a href="#cite_note-:34-31">&#91;31&#93;</a></sup> as well as thinning of the ganglion cell layers in NTG patients compared to other POAG and normal patients<sup id="cite_ref-:35_32-0" class="reference"><a href="#cite_note-:35-32">&#91;32&#93;</a></sup>. In Asian patients this thinning has been correlated with vascular narrowing in asymmetric NTG when compared to normal fellow eyes and POAG patients with elevated pressures<sup id="cite_ref-:36_33-0" class="reference"><a href="#cite_note-:36-33">&#91;33&#93;</a></sup><sup id="cite_ref-:37_34-0" class="reference"><a href="#cite_note-:37-34">&#91;34&#93;</a></sup><sup id="cite_ref-:38_35-0" class="reference"><a href="#cite_note-:38-35">&#91;35&#93;</a></sup>.
</p>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span></h2>
<p>As previously discussed, the mechanism for the development of glaucomatous optic neuropathy is unknown and remains an area of active research and debate. Even less understood is how these pathologic changes occur in the setting of normal IOP levels. Current research is in part directed towards the physiologic forces that affect perfusion of the optic nerve vasculature as well as cellular oxidative changes that occur with changes in perfusion. The relationship between systemic hypertension and hypotension, ocular vascular perfusion pressure, and local regulation of ocular blood flow by vascular tone mediators such as endothelin seem to play a role in maintenance of a constant perfusion of optic nerve tissues. One theory suggests that perturbation of this perfusion by variability in these parameters leads to oxidative stress by the generation of reactive oxygen species resulting in cellular damage, apoptosis of ganglion cells, and tissue remodeling characteristic of glaucomatous optic neuropathy<sup id="cite_ref-:39_36-0" class="reference"><a href="#cite_note-:39-36">&#91;36&#93;</a></sup>. In addition, mechanical factors are being investigated as to their role in the pathogenesis of optic neuropathy. Focal and/or diffuse compromise in the structural integrity of the lamina cribrosa has also been suggested in the pathogenesis of the disease<sup id="cite_ref-:40_37-0" class="reference"><a href="#cite_note-:40-37">&#91;37&#93;</a></sup>. All of these mechanisms need further research to better define the pathophysiology of the disease process.
</p>
<h2><span class="mw-headline" id="Primary_prevention">Primary prevention</span></h2>
<p>Screening for and treatment of risk factors associated with normal tension glaucoma, such as nocturnal hypotension, currently does not have a defined role in primary prevention of the condition. The hope for improved future understanding of the mechanism of disease development may lead to preventive interventions in patients at risk but at this time is not a standard clinical practice. 
</p>
<h1><span class="mw-headline" id="Diagnosis">Diagnosis</span></h1>
<p>As with the broader spectrum of primary open angle glaucoma, the diagnosis is made by perimetric identification of characteristic visual field defects as well as progressive excavation or ‘cupping’ of the optic nerve from focal or diffuse thinning of the optic nerve rim. In addition, the measured IOP must always be less than or equal to 21 mm Hg. 
</p>
<h2><span class="mw-headline" id="History">History</span></h2>
<p>A thorough history is important in the evaluation of the glaucoma suspect patient to uncover evidence of the condition, but also to detect other neurologic conditions that may be masquerading as NTG. A review of accompanied neurologic symptoms such as headache, weakness, dizziness, diplopia, or loss of consciousness should be performed. Particular attention should be given to review of prior episodes of ocular trauma or inflammation as to elucidate possible prior intraocular pressure elevation or other causes of optic neuropathy. Past use of medications, such as systemic, topical, inhaled, or nasal steroids, that can elevate intraocular pressure should be investigated. Inquiries should be made into conditions that may be causal or co-exist with compromised ocular perfusion such as sleep apnea, syncope, Raynauds phenomenon, anemia, hypotension, or prior events of significant vascular compromise requiring blood transfusions. Queries should be made regarding the presence of systemic hypertension or hypotension and any current treatments for these. 
</p>
<h2><span class="mw-headline" id="Physical_examination">Physical examination</span></h2>
<p>Complete ophthalmologic examination is essential as a means of excluding other forms of glaucoma or confounding visually significant conditions (such as other forms of optic neuropathy) that may shape interpretation of subsequent imaging or perimetry testing. Features of the clinical exam should include: 
</p>
<ul><li>Visual acuity</li>
<li>Color vision testing (to help differentiate from non-glaucomatous optic neuropathies)</li>
<li>Intraocular pressure measurement</li>
<li>Diurnal or supine intraocular pressure measurement (if possible)</li>
<li>Pachymetry</li>
<li>Afferent pupillary response testing</li>
<li>Gonioscopy</li>
<li>Complete slit lamp examination of the anterior segment</li>
<li>Dilated fundus examination with optic nerve head and retinal nerve fiber layer (RNFL) assessment</li></ul>
<h2><span class="mw-headline" id="Signs">Signs</span></h2>
<p>Characteristic focal or diffuse thinning of the optic nerve head rim, as discussed above, is the physical examination hallmark of all glaucomatous disease. Characteristically, the following features may be more frequently seen in NTG compared to POAG:
</p>
<ul><li>Flame shaped hemorrhages of the optic nerve rim (Drance hemorrhage) (see <a href="#Figure1">figure 1</a>)</li>
<li>Deep, focal notching of the rim</li>
<li>Peripapillary atrophy</li></ul>
<p><a href="/File:ONH_heme.png" class="image" title="Optic disc photograph of a left eye demonstrating a hemorrhage occurring at the inferotemporal rim."><img alt="Optic disc photograph of a left eye demonstrating a hemorrhage occurring at the inferotemporal rim." src="/w/images/1/c/c1/ONH_heme.png" decoding="async" width="488" height="571" /></a> 
</p><p><span id="Figure1">Figure 1</span>: Optic disc photograph of a left eye demonstrating a hemorrhage occurring at the inferotemporal rim. 
</p>
<h2><span class="mw-headline" id="Symptoms">Symptoms</span></h2>
<p>As with all forms of open angle glaucoma, the condition is typically asymptomatic until very advanced. Patients may occasionally present with a subjective scotoma near fixation as these defects can occur early in the disease process of NTG. 
</p>
<h2><span class="mw-headline" id="Clinical_diagnosis">Clinical diagnosis</span></h2>
<p>Normal tension glaucoma is a diagnosis made based on similar criteria to primary open angle glaucoma but with important clinical distinction. 
</p><p>These features include:
</p>
<ul><li>Progressive excavation or ‘cupping’ of the optic nerve head from retinal nerve fiber layer loss resulting in corresponding visual field deficits.</li>
<li>Gonioscopic confirmation of open anterior chamber angle and absence of findings consistent with pigment dispersion or pseudoexfoliation syndrome.</li>
<li>Pre-treatment IOP must always be &lt;22 mm Hg. (diurnal measurement of IOP to ensure there is not a circadian elevation in pressure that is missed by single period clinical measurement)</li></ul>
<p><br />
The diagnosis of NTG is only reached once other forms of optic neuropathy have been ruled out (e.g. ischemic, traumatic, toxic inflammatory, infectious, congenital, and compressive). 
</p><p>Careful history taking should be undertaken to elucidate any prior events that can mimic NTG such as: 
</p>
<ul><li>Traumatic injuries</li>
<li>Inflammation</li>
<li>Severe blood-loss or hypotensive events</li>
<li>Medications that may precipitate a transient pathologic elevation in IOP</li></ul>
<p><br />
After reasonable exclusion of all other etiologies, the demonstration of visual field loss on static, or less often kinetic, perimetry in conjunction with characteristic optic nerve central cupping with no elevation in IOP above 21 mm Hg cement the diagnosis. 
</p><p>Other classically associated examination findings with NTG that can be helpful clues in raising suspicion for pursuing a diagnosis include optic nerve or “Drance” hemorrhages and peripapillary atrophy. While these findings are not specific, patients with NTG have a higher propensity for optic nerve hemorrhages compared to patients with POAG. Focal defects in the retinal nerve fiber layer may be more commonly observed as well. 
</p>
<h2><span class="mw-headline" id="Diagnostic_procedures">Diagnostic procedures</span></h2>
<h3><span class="mw-headline" id="Visual_field_testing">Visual field testing</span></h3>
<p>Automated static perimetry is the most common modality used to detect and monitor for progression of the field loss associated with normal tension glaucoma. Visual field defects may include those common to POAG including nasal step and arcuate scotoma. However, defects noted in NTG tend to be more focal and occur closer to fixation early in the disease (<a href="#Figure2">Figure 2a,b</a>). Dense paracentral scotomas may characteristically be noted at initial diagnosis. For a full discussion of visual field testing see the main article “<a rel="nofollow" class="external text" href="https://eyewiki.aao.org/Standard_Automated_Perimetry">Standard Automated Perimetry</a>.” 
</p><p>a)<a href="/File:HVF_left.png" class="image"><img alt="HVF left.png" src="/w/images/1/d/d9/HVF_left.png" decoding="async" width="314" height="334" /></a>&#160;b)<a href="/File:HVF_right.png" class="image"><img alt="HVF right.png" src="/w/images/1/0/02/HVF_right.png" decoding="async" width="309" height="331" /></a> 
</p><p><span id="Figure2">Figure 2</span>: Standard automated perimetry of a) left and b) right eye in a patient with normal tension glaucoma. Note the dense inferior arcuate scotomas occurring near fixation with minimal involvement of periphery. The corresponding optic nerve head changes are seen in <a href="#Figure3">Figure 3</a>.<br /> 
</p>
<h3><span class="mw-headline" id="Optic_disc_imaging">Optic disc imaging</span></h3>
<p>Due to the irreversible loss of vision due to glaucomatous damage, early detection and treatment is paramount. Visual field testing is useful in early detection but may miss early, pre-perimetric disease, as substantial retinal nerve fiber layer may be lost before functional field defects are noted. Therefore optic disc imaging is an important and objective structural assessment of the optic nerve health. For several decades, the gold standard for detecting disease and monitoring changes in the optic nerve head has been stereo disc photography (<a href="#Figure3">Figure 3 a,b</a>). In recent years, scanning laser ophthalmoscopy and optical coherence tomography (OCT) is gaining popularity as another means of detecting pathologic thinning of neural tissue and monitoring progression. (See main article on&#160;<a rel="nofollow" class="external text" href="https://eyewiki.aao.org/Optic_Nerve_and_Retinal_Nerve_Fiber_Imaging">eyewiki.aao.org/Optic_Nerve_and_Retinal_Nerve_Fiber_Imaging</a> ) 
</p><p>a)&#160;<a href="/File:Notch_right.png" class="image"><img alt="Notch right.png" src="/w/images/1/3/36/Notch_right.png" decoding="async" width="395" height="373" /></a>&#160;b)&#160;<a href="/File:Notch_left.png" class="image"><img alt="Notch left.png" src="/w/images/1/8/8b/Notch_left.png" decoding="async" width="384" height="370" /></a> 
</p><p><span id="Figure3">Figure 3</span>: Optic disc photographs of a) right and b) left eye in a patient with normal tension glaucoma. Note the focal superotemporal thinning and associated dropout of the retinal nerve fiber layer. The corresponding visual field defects are seen in <a href="#Figure2">Figure 2</a>.
</p>
<h3><span class="mw-headline" id="Pachymetry">Pachymetry</span></h3>
<p>Assessment of central corneal thickness (CCT) through pachymetry is essential in the work up of normal tension glaucoma. The measured IOP by applanation may be artifactually low in eyes with low CCT. Many patients with a diagnosis of NTG will demonstrate a low CCT. In some cases, correction of this under measurement (based on published correction factors<sup id="cite_ref-:41_38-0" class="reference"><a href="#cite_note-:41-38">&#91;38&#93;</a></sup>) may reveal an actual IOP more consistent with POAG <sup id="cite_ref-:42_39-0" class="reference"><a href="#cite_note-:42-39">&#91;39&#93;</a></sup>.
</p>
<h3><span id="Neurological_Evaluation/Work-Up"></span><span class="mw-headline" id="Neurological_Evaluation.2FWork-Up">Neurological Evaluation/Work-Up</span></h3>
<p>At times, the diagnosis of NTG may simulate other neurological conditions such as those listed in the differential diagnosis section below. Most concerning to the clinician is an intracranial tumor masquerading as NTG. While these diagnoses are rare, clinicians should maintain a low threshold for neuroimaging with CT or MRI and a full neurological evaluation whenever the following exist:
</p>
<ul><li>Marked asymmetry or unilateral optic nerve involvement</li>
<li>Unexplained visual acuity loss</li>
<li>Color vision deficits in the absence of visual field deficits</li>
<li>Visual field defects not corresponding or out of proportion to optic nerve damage</li>
<li>Vertically aligned visual field defects</li>
<li>Atypical neurologic symptoms for glaucoma</li>
<li>Optic nerve pallor in excess of cupping</li>
<li>Age less than 50 years</li></ul>
<h2><span class="mw-headline" id="Differential_diagnosis">Differential diagnosis</span></h2>
<h3><span class="mw-headline" id="Glaucomatous_etiology">Glaucomatous etiology</span></h3>
<ul><li>Primary open angle glaucoma with diurnal fluctuation between normal and elevated IOP</li>
<li>Intermittent acute angle closure glaucoma</li>
<li>Tonometric underestimation of actual IOP (e.g. thin central corneas)</li>
<li>Resolved corticosteroid-induced, uveitic, or traumatic glaucoma</li>
<li>Uveitic glaucoma/glaucomatocyclitic crisis (Posner-Schlossman)</li>
<li>‘Burned out’ pigmentary glaucoma</li>
<li>Myopia with peripapillary atrophy</li>
<li>Optic nerve coloboma or pits</li>
<li>Congenital disc anomalies/cupping</li></ul>
<p><br />
</p>
<h3><span id="Compressive,_metabolic,_toxic,_inflammatory_or_infectious_optic_neuropathy"></span><span class="mw-headline" id="Compressive.2C_metabolic.2C_toxic.2C_inflammatory_or_infectious_optic_neuropathy">Compressive, metabolic, toxic, inflammatory or infectious optic neuropathy</span></h3>
<ul><li>Pituitary Adenoma</li>
<li>Meningioma</li>
<li>Empty sella syndrome</li>
<li>Leber’s optic atrophy</li>
<li>Methanol optic neuropathy</li>
<li>Optic neuritis</li>
<li>Syphilis</li></ul>
<p><br />
</p>
<h3><span class="mw-headline" id="Vascular_injuries">Vascular injuries</span></h3>
<ul><li>Giant cell arteritis</li>
<li>Non-arteritic anterior ischemic optic neuropathy</li>
<li>Posterior ischemic optic neuropathy</li>
<li>Central retinal artery occlusion</li>
<li>Carotid/ophthalmic artery occlusion<sup id="cite_ref-:43_40-0" class="reference"><a href="#cite_note-:43-40">&#91;40&#93;</a></sup></li></ul>
<h1><span class="mw-headline" id="Management">Management</span></h1>
<h2><span class="mw-headline" id="General_treatment">General treatment</span></h2>
<p>In general, management of normal tension glaucoma mirrors the medical and surgical management of the other forms of glaucoma and hinges on reduction of IOP from baseline. Identification of patients with clinical evidence of progression is important in the decision to initiate treatment for NTG. The natural history of NTG does not always include progression without treatment. As initially described by Drance, a significant portion of patients with normal tension glaucoma may not demonstrate clinical progression regardless of treatment<sup id="cite_ref-drance17_17-1" class="reference"><a href="#cite_note-drance17-17">&#91;17&#93;</a></sup>.These patients typically had a history of systemic vascular compromise resulting in a one-time insult to the optic nerve. Nonetheless, for the majority of patients with NTG, reduction of IOP remains the focus of treatment. 
</p><p>The Collaborative Normal Tension Glaucoma Study (CNTGS) demonstrated the benefit of IOP reduction for the treatment of patients with NTG<sup id="cite_ref-ntgsg18_18-1" class="reference"><a href="#cite_note-ntgsg18-18">&#91;18&#93;</a></sup><sup id="cite_ref-ntgsg19_19-1" class="reference"><a href="#cite_note-ntgsg19-19">&#91;19&#93;</a></sup>. The study concluded that a 30 percent reduction in baseline IOP resulted in a reduced risk of disease progression. Criteria for initiation of treatment of the NTG patients in this study were defined as: documented visual field or optic nerve progression, visual field loss threatening fixation, or presence of disc hemorrhage. The treatment group had a 12% risk of progression at 5 years compared to 35% progressing in the non-treatment group<sup id="cite_ref-ntgsg19_19-2" class="reference"><a href="#cite_note-ntgsg19-19">&#91;19&#93;</a></sup>. The CNTGS trial was therefore instrumental in demonstrating the role of IOP in the pathogenesis of NTG and the benefit of treatment to lower it. The study also presents a reasonable goal for treatment in 30% IOP reduction from patient’s baseline. Treatment IOP goals may then be modified over the course of treatment to a level that sufficiently prevents or slows progression of disease. 
</p><p>Outside of IOP lowering therapy, other aspects should be considered in the management of NTG patients. This may include cardiovascular problems such as systemic hypotension, nocturnal hypotension, anemia, and cardiac arrhythmias that can compromise optic nerve head perfusion. Consultation with primary care physicians can be helpful in addressing these concerns, but limited evidence is available to confirm a treatment benefit for NTG.
</p>
<h2><span class="mw-headline" id="Medical_therapy">Medical therapy</span></h2>
<p>Topical IOP lowering medications including prostaglandin analogues, alpha-2 agonists, beta-blockers, carbonic anhydrase inhibitors, and more recently Rho-kinase inhibitors are the mainstays of medical therapy. Medications should be chosen on an individual basis to provide treatment that achieves a sufficient IOP reduction with minimal side effects and ease of administration. Medication choice should also be cost-effective for the patient based on their resources. For a full discussion of medical management please see the POAG main article. 
</p><p>Particularly with NTG, the effect of medications on systemic blood pressure, heart rate, and optic nerve perfusion should be considered. Furthermore, medications that have neuroprotective or IOP independent effects would be extremely beneficial and remain an ongoing search. The Low-Pressure Glaucoma Study (LoGTS) demonstrated the importance of IOP independent factors when choosing medical therapy for NTG<sup id="cite_ref-krupin27_27-1" class="reference"><a href="#cite_note-krupin27-27">&#91;27&#93;</a></sup>. In this prospective trial, patients with low-tension glaucoma were randomized to treatment with either brimonidine tartrate 0.2% or timolol maleate 0.5%. While IOP reduction was similar between the two treatment groups, patients treated with brimonidine were less likely to have visual field progression compared to patients treated with timolol. It is unclear whether this difference is due to an additional neuroprotective effect of brimonidine or a detrimental vascular effect from timolol. Moreover, Rho-kinase inhibitors are thought to be neuroprotective and increase vascular flow at the ONH via the nitric oxide pathway <sup>[65] [66]</sup>. Further trials are needed to identify ideal medical therapy in patients with NTG. 
</p><p>In patients with evidence of vasospasm, calcium channel blockers have been proposed to stabilize vascular tone, particularly in patients with concurrent hypertension, though the benefit has not been evaluated in large clinical trials.
</p>
<h2><span class="mw-headline" id="Medical_follow_up">Medical follow up</span></h2>
<p>Once treatment is initiated, patients should be followed up 6-8 weeks later to ensure good adherence, minimal side effects, and adequate IOP lowering efficacy. Different medication classes, laser treatment or surgical therapy may be trialed until an appropriate treatment is found. Once treatment goals have been met, periodic measurement of IOP during medical therapy is recommended every 3-4 months to ensure maintenance of goal IOP and absence of progression. Patients should be monitored for signs of progression by periodic assessment of the optic nerve head (disc photos, HRT, OCT, etc.) and visual field testing every 6-12 months, with more frequent intervals in advanced or actively progressing disease. If progression is detected despite goal IOP, treatment goals should be lowered with advance of therapy to achieve them. (also see: <a href="/Primary_Open-Angle_Glaucoma" title="Primary Open-Angle Glaucoma">Primary_Open-Angle_Glaucoma</a>) 
</p>
<h2><span class="mw-headline" id="Surgery">Surgery</span></h2>
<p>Laser and surgical treatment options for NTG mirror those for POAG. These include laser trabeculoplasty, minimally invasive glaucoma surgery (MIGS), trabeculectomy, and glaucoma drainage devices.
</p><p>Selective Laser trabeculoplasty (SLT) may be a useful moderately invasive treatment with or without medical therapy. Indeed, there is some literature that supports an IOP lowering, and decreased IOP variability, effect of SLT in NTG patients <sup>[62]</sup>. For patients with IOP targets that are not achievable with medical/laser therapy, filtration surgery with or without a drainage device has traditionally been the mainstay of surgically lowering IOP. However, recent trends and practice patterns according to the AAO Intelligent Research Insight Registry (IRIS) reveal a significant increase in the use of MIGS procedures from 2013-2018, and NTG is no exception <sup>[63]</sup>.
</p><p>Minimally invasive glaucoma procedures such as goniotomy with Kahook Dual Blade (KDB), the iStent trabecular bypass device, and the XEN gel stent have demonstrated an important although limited role in the surgical management of NTG. In theory, angle-based MIGS procedures can only lower IOP to a level equal to or above episcleral venous pressure of approximately 8-11 mm Hg. &#160;Goal IOP for NTG patients may be below this level making it difficult to achieve treatment goals by surgical means alone. However, maintaining a goal IOP with fewer medications is a reasonable indication for MIGS in NTG.&#160; This rationale also applies to laser trabeculoplasty, which augments aqueous outflow to the downstream episcleral venous system as well. According to AAO IRIS data regarding initial surgery for NTG, iStent has been the most common performed surgery and MIGS procedures in general are performed at a higher rate than filtration surgeries for NTG <sup>[64]</sup>.
</p><p>In the CNTGS, the IOP reduction of 30% was only achieved in 57% of patients by topical medication and/or laser trabeculoplasty, while the remaining 43% required filtering surgery . While IOP lowering with filtration surgery has been shown to be effective in decreasing visual field progression a continued, slowed progression has been reported in postoperative patients followed for up to 6 years .
</p><p>A lower starting IOP with NTG patients and a 30% reduction target may result in a narrower margin between therapeutic IOP reduction and hypotony in these patients. Indeed, increase risk of filtering surgery complications has been reported in this subset of POAG patients .
</p><p>Selection of anti-metabolite drugs and means of application in filtering surgery is an important consideration and should be guided by specific treatment goals and surgeon specific experience with these agents. Mitomycin C (MMC) has been associated with achievement of lower IOPs post operatively compared to 5-fluorouracil (5-FU) in some studies, &#160;though literature also suggests equivalence of efficacy of these two agents in primary trabeculectomy for POAG . MMC use in NTG glaucoma has an associated increased risk of over-filtration complications that may play a role in the risk of visual field progression . Therefore, meticulous use of MMC (e.g. 0.2-0.4 mg/ml for 1-3 minutes), careful flap suturing, and judicious use of viscoelastic with frequent postoperative follow up have been proposed as methods to mitigate the risks of hypotony early in the post operative phase while achieving target IOP . Early suture lysis may be required to achieve low target IOPs but should be weighed against the risk of resultant over-filtration. Given the context of a higher risk of hypotony following filtering surgery in patients with NTG, the XEN gel stent has recently been deployed to achieve a lower IOP goal while maintaining a lower rate of hypotony. One recent study demonstrated a mean IOP decrease of 5.6 +/- 2.7 mmHg in NTG patients, which represented an IOP reduction of 29% <sup>[67]</sup>. Also, the use of the EX-PRESS glaucoma mini shunt has been employed as a means of preventing complications, while still achieving similar IOP goals compared to standard trabeculectomy . In our experience, the smaller, consistent outflow opening of the EX-PRESS shunt allows for earlier suture lysis to achieve low IOP targets with less risk of hypotony. The utility of this device remains an area of debate considering the additional cost of the device and mixed outcomes in the literature.
</p><p>Cyclodestructive procedures provide the only surgical means of suppressing aqueous production to lower IOP. Due to their potentially vision threatening side effects, these procedures are typically reserved for eyes refractory to treatment or with poor visual potential. Ablation of the ciliary processes may be accomplished by transscleral cyclophotocoagulation (CPC) or by endoscopic cyclophotocoagulation (ECP). ECP offers the unique advantage of direct visualization of the target tissue allowing a more targeted approach to achieve less inflammation and side effects.
</p><p>(For full discussion of surgical management see: <a href="/Primary_Open-Angle_Glaucoma" title="Primary Open-Angle Glaucoma">Primary_Open-Angle_Glaucoma</a>).
</p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span></h2>
<p>Like any form of glaucoma, NTG may progress to irreversible blindness. The prognosis for visual preservation is good in patients who undergo adequate treatment through IOP reduction. In the CNTGS trial, 65% of patients in the control group with NTG did not progress even without treatment<sup id="cite_ref-ntgsg19_19-3" class="reference"><a href="#cite_note-ntgsg19-19">&#91;19&#93;</a></sup>. However an IOP reduction of 30% with treatment further lowered the likelihood of progression to only 12%. As mentioned previously, patients with NTG that previously suffered an acute vascular compromise have also been shown to not progress over time as well. Given this relatively high rate of non-progression, some clinicians have suggested a conservative “wait and see” approach to initiating treatment. This recommendation should be cautioned, as it is often difficult to determine which patients will progress, and other studies have shown variable rates of progression in this disease. Risk factors for progression of visual field defects in NTG include migraine, disc hemorrhage, and female gender. Asians have been shown to have a slower rate of progression<sup id="cite_ref-drance57_41-0" class="reference"><a href="#cite_note-drance57-41">&#91;41&#93;</a></sup>.
</p>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-:1-1"><span class="mw-cite-backlink"><a href="#cite_ref-:1_1-0">↑</a></span> <span class="reference-text">Graefe, A.V., Uber die iridectomie bei glaucom und uber den glaucomatasen prozess. . Graefes Arch Clin Exp Ophthalmol, 1857. 1857(3): p. 456–465.</span>
</li>
<li id="cite_note-:2-2"><span class="mw-cite-backlink"><a href="#cite_ref-:2_2-0">↑</a></span> <span class="reference-text">Lee, B.L., R. Bathija, and R.N. Weinreb, The definition of normal-tension glaucoma. J Glaucoma, 1998. 7(6): p. 366-71.</span>
</li>
<li id="cite_note-:3-3"><span class="mw-cite-backlink"><a href="#cite_ref-:3_3-0">↑</a></span> <span class="reference-text">Levene, R.Z., Low tension glaucoma. Part II. Clinical characteristics and pathogenesis. Ann Ophthalmol, 1980. 12(12): p. 1383.</span>
</li>
<li id="cite_note-:4-4"><span class="mw-cite-backlink"><a href="#cite_ref-:4_4-0">↑</a></span> <span class="reference-text">Levene, R.Z., Low tension glaucoma: a critical review and new material. Surv Ophthalmol, 1980. 24(6): p. 621-64.</span>
</li>
<li id="cite_note-:5-5"><span class="mw-cite-backlink"><a href="#cite_ref-:5_5-0">↑</a></span> <span class="reference-text">Armaly, M.F., Age and sex correction of applanation pressure. Arch Ophthalmol, 1967. 78(4): p. 480-4.</span>
</li>
<li id="cite_note-:6-6"><span class="mw-cite-backlink"><a href="#cite_ref-:6_6-0">↑</a></span> <span class="reference-text">Colton, T. and F. Ederer, The distribution of intraocular pressures in the general population. Surv Ophthalmol, 1980. 25(3): p. 123-9.</span>
</li>
<li id="cite_note-:7-7"><span class="mw-cite-backlink"><a href="#cite_ref-:7_7-0">↑</a></span> <span class="reference-text">David, R., et al., Epidemiology of intraocular pressure in a population screened for glaucoma. Br J Ophthalmol, 1987. 71(10): p. 766-71.</span>
</li>
<li id="cite_note-:8-8"><span class="mw-cite-backlink"><a href="#cite_ref-:8_8-0">↑</a></span> <span class="reference-text">Klein, B.E., R. Klein, and K.L. Linton, Intraocular pressure in an American community. The Beaver Dam Eye Study. Invest Ophthalmol Vis Sci, 1992. 33(7): p. 2224-8.</span>
</li>
<li id="cite_note-:9-9"><span class="mw-cite-backlink"><a href="#cite_ref-:9_9-0">↑</a></span> <span class="reference-text">Loewen, U., B. Handrup, and A. Redeker, [Results of a glaucoma mass screening program (author's transl)]. Klin Monbl Augenheilkd, 1976. 169(6): p. 754-66.</span>
</li>
<li id="cite_note-:10-10"><span class="mw-cite-backlink"><a href="#cite_ref-:10_10-0">↑</a></span> <span class="reference-text">Perkins, E.S., Glaucoma Screening from a Public Health Clinic. Br Med J, 1965. 1(5432): p. 417-9.</span>
</li>
<li id="cite_note-:11-11"><span class="mw-cite-backlink"><a href="#cite_ref-:11_11-0">↑</a></span> <span class="reference-text">Ruprecht, K.W., K.G. Wulle, and H.L. Christl, [Applanation tonometry within medical diagnostic "check-up" programs (author's transl)]. Klin Monbl Augenheilkd, 1978. 172(3): p. 332-41.</span>
</li>
<li id="cite_note-:12-12"><span class="mw-cite-backlink"><a href="#cite_ref-:12_12-0">↑</a></span> <span class="reference-text">Segal, P. and J. Skwierczynska, Mass screening of adults for glaucoma. Ophthalmologica, 1967. 153(5): p. 336-48.</span>
</li>
<li id="cite_note-:13-13"><span class="mw-cite-backlink"><a href="#cite_ref-:13_13-0">↑</a></span> <span class="reference-text">Shiose, Y. and Y. Kawase, A new approach to stratified normal intraocular pressure in a general population. Am J Ophthalmol, 1986. 101(6): p. 714-21.</span>
</li>
<li id="cite_note-:14-14"><span class="mw-cite-backlink"><a href="#cite_ref-:14_14-0">↑</a></span> <span class="reference-text">Armaly, M.F., On the Distribution of Applanation Pressure. I. Statistical Features and the Effect of Age, Sex, and Family History of Glaucoma. Arch Ophthalmol, 1965. 73: p. 11-8.</span>
</li>
<li id="cite_note-leydhecker15-15"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-leydhecker15_15-0">15.0</a></sup> <sup><a href="#cite_ref-leydhecker15_15-1">15.1</a></sup></span> <span class="reference-text">Leydhecker, W., K. Akiyama, and H.G. Neumann, [Intraocular pressure in normal human eyes]. Klin Monbl Augenheilkd Augenarztl Fortbild, 1958. 133(5): p. 662-70.</span>
</li>
<li id="cite_note-:16-16"><span class="mw-cite-backlink"><a href="#cite_ref-:16_16-0">↑</a></span> <span class="reference-text">Sommer, A., et al., Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol, 1991. 109(8): p. 1090-5.</span>
</li>
<li id="cite_note-drance17-17"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-drance17_17-0">17.0</a></sup> <sup><a href="#cite_ref-drance17_17-1">17.1</a></sup></span> <span class="reference-text">Drance, S.M., R.W. Morgan, and V.P. Sweeney, Shock-induced optic neuropathy: a cause of nonprogressive glaucoma. N Engl J Med, 1973. 288(8): p. 392-5.</span>
</li>
<li id="cite_note-ntgsg18-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ntgsg18_18-0">18.0</a></sup> <sup><a href="#cite_ref-ntgsg18_18-1">18.1</a></sup></span> <span class="reference-text">The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol, 1998. 126(4): p. 498-505.</span>
</li>
<li id="cite_note-ntgsg19-19"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ntgsg19_19-0">19.0</a></sup> <sup><a href="#cite_ref-ntgsg19_19-1">19.1</a></sup> <sup><a href="#cite_ref-ntgsg19_19-2">19.2</a></sup> <sup><a href="#cite_ref-ntgsg19_19-3">19.3</a></sup></span> <span class="reference-text">Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol, 1998. 126(4): p. 487-97.</span>
</li>
<li id="cite_note-:20-20"><span class="mw-cite-backlink"><a href="#cite_ref-:20_20-0">↑</a></span> <span class="reference-text">Burk, R.O., et al., Are large optic nerve heads susceptible to glaucomatous damage at normal intraocular pressure? A three-dimensional study by laser scanning tomography. Graefes Arch Clin Exp Ophthalmol, 1992. 230(6): p. 552-60.</span>
</li>
<li id="cite_note-:21-21"><span class="mw-cite-backlink"><a href="#cite_ref-:21_21-0">↑</a></span> <span class="reference-text">Tuulonen, A., et al., Optic disk cupping and pallor measurements of patients with a disk hemorrhage. Am J Ophthalmol, 1987. 103(4): p. 505-11.</span>
</li>
<li id="cite_note-:22-22"><span class="mw-cite-backlink"><a href="#cite_ref-:22_22-0">↑</a></span> <span class="reference-text">Vogel, W., et al., Delayed clearance of HBsAG after transplantation for fulminant delta-hepatitis. Lancet, 1988. 1(8575-6): p. 52.</span>
</li>
<li id="cite_note-:23-23"><span class="mw-cite-backlink"><a href="#cite_ref-:23_23-0">↑</a></span> <span class="reference-text">Buus, D.R. and D.R. Anderson, Peripapillary crescents and halos in normal-tension glaucoma and ocular hypertension. Ophthalmology, 1989. 96(1): p. 16-9.</span>
</li>
<li id="cite_note-:24-24"><span class="mw-cite-backlink"><a href="#cite_ref-:24_24-0">↑</a></span> <span class="reference-text">Yamazaki, Y., et al., Optic disc findings in normal tension glaucoma. Jpn J Ophthalmol, 1997. 41(4): p. 260-7.</span>
</li>
<li id="cite_note-:25-25"><span class="mw-cite-backlink"><a href="#cite_ref-:25_25-0">↑</a></span> <span class="reference-text">Anderson, D.R. and S. Normal Tension Glaucoma, Collaborative normal tension glaucoma study. Curr Opin Ophthalmol, 2003. 14(2): p. 86-90.</span>
</li>
<li id="cite_note-gramer26-26"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-gramer26_26-0">26.0</a></sup> <sup><a href="#cite_ref-gramer26_26-1">26.1</a></sup></span> <span class="reference-text">Gramer, E. and W. Leydhecker, [Glaucoma without ocular hypertension. A clinical study]. Klin Monbl Augenheilkd, 1985. 186(4): p. 262-7.</span>
</li>
<li id="cite_note-krupin27-27"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-krupin27_27-0">27.0</a></sup> <sup><a href="#cite_ref-krupin27_27-1">27.1</a></sup></span> <span class="reference-text">Krupin T., et al., A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol, 2011. 151(4): p. 671-81.</span>
</li>
<li id="cite_note-:31-28"><span class="mw-cite-backlink"><a href="#cite_ref-:31_28-0">↑</a></span> <span class="reference-text">Phelps, C.D. and J.J. Corbett, Migraine and low-tension glaucoma. A case-control study. Invest Ophthalmol Vis Sci, 1985. 26(8): p. 1105-8.</span>
</li>
<li id="cite_note-:32-29"><span class="mw-cite-backlink"><a href="#cite_ref-:32_29-0">↑</a></span> <span class="reference-text">Flammer, J., K. Konieczka, and A.J. Flammer, The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J, 2013. 4(1): p. 14.</span>
</li>
<li id="cite_note-:33-30"><span class="mw-cite-backlink"><a href="#cite_ref-:33_30-0">↑</a></span> <span class="reference-text">Hollander, R., [The Influence of the Permeability of the Cell Membrane on TMPD Oxydase Activity (author's transl)]. Zentralbl Bakteriol Orig A, 1977. 237(2-3): p. 351-7.</span>
</li>
<li id="cite_note-:34-31"><span class="mw-cite-backlink"><a href="#cite_ref-:34_31-0">↑</a></span> <span class="reference-text">Hirooka, K., et al., Evaluation of peripapillary choroidal thickness in patients with normal-tension glaucoma. BMC Ophthalmol, 2012. 12: p. 29.</span>
</li>
<li id="cite_note-:35-32"><span class="mw-cite-backlink"><a href="#cite_ref-:35_32-0">↑</a></span> <span class="reference-text">Firat, P.G., et al., Evaluation of peripapillary retinal nerve fiber layer, macula and ganglion cell thickness in amblyopia using spectral optical coherence tomography. Int J Ophthalmol, 2013. 6(1): p. 90-4.</span>
</li>
<li id="cite_note-:36-33"><span class="mw-cite-backlink"><a href="#cite_ref-:36_33-0">↑</a></span> <span class="reference-text">Zheng, Y., et al., Relationship of retinal vascular caliber with retinal nerve fiber layer thickness: the singapore malay eye study. Invest Ophthalmol Vis Sci, 2009. 50(9): p. 4091-6.</span>
</li>
<li id="cite_note-:37-34"><span class="mw-cite-backlink"><a href="#cite_ref-:37_34-0">↑</a></span> <span class="reference-text">Kim, J.M., et al., The association between retinal vessel diameter and retinal nerve fiber layer thickness in asymmetric normal tension glaucoma patients. Invest Ophthalmol Vis Sci, 2012. 53(9): p. 5609-14.</span>
</li>
<li id="cite_note-:38-35"><span class="mw-cite-backlink"><a href="#cite_ref-:38_35-0">↑</a></span> <span class="reference-text">Lee, J.Y., et al., Retinal vessel diameter in young patients with open-angle glaucoma: comparison between high-tension and normal-tension glaucoma. Acta Ophthalmol, 2012. 90(7): p. e570-1.</span>
</li>
<li id="cite_note-:39-36"><span class="mw-cite-backlink"><a href="#cite_ref-:39_36-0">↑</a></span> <span class="reference-text">Mozaffarieh, M. and J. Flammer, New insights in the pathogenesis and treatment of normal tension glaucoma. Curr Opin Pharmacol, 2013. 13(1): p. 43-9.</span>
</li>
<li id="cite_note-:40-37"><span class="mw-cite-backlink"><a href="#cite_ref-:40_37-0">↑</a></span> <span class="reference-text">Crawford Downs, J., M.D. Roberts, and I.A. Sigal, Glaucomatous cupping of the lamina cribrosa: a review of the evidence for active progressive remodeling as a mechanism. Exp Eye Res, 2011. 93(2): p. 133-40.</span>
</li>
<li id="cite_note-:41-38"><span class="mw-cite-backlink"><a href="#cite_ref-:41_38-0">↑</a></span> <span class="reference-text">Shih, C.Y., et al., Clinical significance of central corneal thickness in the management of glaucoma. Arch Ophthalmol, 2004. 122(9): p. 1270-5.</span>
</li>
<li id="cite_note-:42-39"><span class="mw-cite-backlink"><a href="#cite_ref-:42_39-0">↑</a></span> <span class="reference-text">Shetgar, A.C. and M.B. Mulimani, The central corneal thickness in normal tension glaucoma, primary open angle glaucoma and ocular hypertension. J Clin Diagn Res, 2013. 7(6): p. 1063-7.</span>
</li>
<li id="cite_note-:43-40"><span class="mw-cite-backlink"><a href="#cite_ref-:43_40-0">↑</a></span> <span class="reference-text">Tsai, J. and M.A. Karim, Current concepts in normal tension glaucoma. Review of Ophthalmology, 2006. 6(24).</span>
</li>
<li id="cite_note-drance57-41"><span class="mw-cite-backlink"><a href="#cite_ref-drance57_41-0">↑</a></span> <span class="reference-text">Drance, S., et al., Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol, 2001. 131(6): p. 699-708.</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035157
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.022 seconds
CPU time usage: 0.234 seconds
Real time usage: 1.430 seconds
Preprocessor visited node count: 1071/1000000
Post‐expand include size: 7007/2097152 bytes
Template argument size: 1593/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 1/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 17777/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  686.200      1 Template:Article
100.00%  686.200      1 -total
 87.13%  597.918      4 Template:Infobox_section
 30.09%  206.471     10 Template:UserLookup
  6.37%   43.719      1 Template:Review_expired
  6.27%   43.053      1 Template:Infobox_begin
  4.07%   27.946      1 Template:Infobox_end
  0.82%    5.609      1 Template:Get_active_contest
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Normal_Tension_Glaucoma&amp;oldid=79297">https://eyewiki.org/w/index.php?title=Normal_Tension_Glaucoma&amp;oldid=79297</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzyxfc7w">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Normal_Tension_Glaucoma" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Normal_Tension_Glaucoma" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Normal_Tension_Glaucoma&amp;oldid=79297" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Normal_Tension_Glaucoma&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on April 1, 2022, at 07:29.</div>
					<div>This page has been accessed 201,571 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.022},"limitreport":{"cputime":"0.234","walltime":"1.430","ppvisitednodes":{"value":1071,"limit":1000000},"postexpandincludesize":{"value":7007,"limit":2097152},"templateargumentsize":{"value":1593,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":1,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":17777,"limit":5000000},"timingprofile":["100.00%  686.200      1 Template:Article","100.00%  686.200      1 -total"," 87.13%  597.918      4 Template:Infobox_section"," 30.09%  206.471     10 Template:UserLookup","  6.37%   43.719      1 Template:Review_expired","  6.27%   43.053      1 Template:Infobox_begin","  4.07%   27.946      1 Template:Infobox_end","  0.82%    5.609      1 Template:Get_active_contest"]},"cachereport":{"timestamp":"20230306035157","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":2042});});</script></body>
</html>